Keri Toner

7PUBLICATIONS
36CO-AUTHORS
Innate immunityHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 24, 2025
Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.

Keri Toner, Lindsay A Renfro, Hema Dave

|Jan 22, 2025
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era.

Lianna J Marks, Victor Ritter, Jennifer E Agrusa

|Jan 01, 2024
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Birte Wistinghausen, Keri Toner, Donald A Barkauskas

|Nov 29, 2023
Overcoming barriers to drug development and enrollment in clinical trials for adolescents and young adults with lymphoma.

Keri Toner, Carl E Allen, Shweta Jain

|Sep 08, 2021
Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.

Hema Dave, Madeline Terpilowski, Mimi Mai

|Aug 26, 2021
EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target.

Keri Toner, Catherine M Bollard

Pageof 2

Frequent Collaborators

2 joint publications

Hema Dave

1 joint publications

Catherine M Bollard

1 joint publications

Melanie Grant

1 joint publications

Reuven Schore